Diana S.M. Buist is an American epidemiologist. She is a senior investigator and director of research and strategic partnerships at Kaiser Permanente Washington Research Institute.
Diana Buist | |
|---|---|
| Spouse | Ky Haverkamp |
| Academic background | |
| Education | PhD, Epidemiology, 1999, University of Washington MPH, Epidemiology, 1995, Yale University |
| Thesis | Bone mineral density and endogenous hormones and breast cancer risk (1999) |
| Academic work | |
| Institutions | Kaiser Permanente |
Early life and education
editBuist was born to the United Kingdom born physician-researchers Sonia and Neil Buist.[1] She earned her PhD in epidemiology from the University of Washington and her MPH in the same subject from Yale University.[2]
Career
editUpon earning her PhD, Buist joined the faculty at the Kaiser Permanente Washington Research Institute (formerly known as the Group Health Research Institute) in 1996.[3] She earned her doctorate degree while working full-time as a research associate in Kaiser Permanente women's health group.[4] In 2003, Buist was appointed the leader of the Breast Cancer Surveillance Consortium registry in Washington.[1] While serving in this role, she received $4 million in federal stimulus funding for her research into improving screening for colorectal and cervical cancer.[5] A few years later, Buist was the senior investigator in a study which found that when women quit hormone therapy, their rates of new breast cancer declined.[6]
In 2015, Buist was named the Group Health Research Institute's director of research and strategic partnerships, while continuing her work as a senior investigator pursuing funded scientific research.[3] During the same year, she co-authored a study with Constance D. Lehman and Diana L. Miglioretti which found that computer-aided detection for breast cancer screening was not as effective as previously conceived.[7] In 2019, Buist was the co-author of another research project which determined a self-collected HPV test provided similar results to those of a physician-collected sample.[8]
Selected publications
edit- Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women (2000)
- Prospective breast cancer risk prediction model for women undergoing screening mammography (2006)
Personal life
editBuist and her husband Ky Haverkamp have two daughters together, Bryn Buist-Haverkamp & Abby Buist-Haverkamp.[4]
References
edit- ^ a b "Cancer research: 5 questions with Diana Buist, PhD". kaiserpermanente.org. October 22, 2018. Retrieved October 20, 2020.
- ^ "DIANA BUIST". epi.washington.edu. Retrieved October 20, 2020.
- ^ a b DeClaire, Joan (December 2, 2015). "GHRI names new director of research and strategic partnerships". kpwashingtonresearch.org. Retrieved October 20, 2020.
- ^ a b "What drives Diana Buist to study breast cancer screening?". kpwashingtonresearch.org. October 23, 2018. Retrieved October 20, 2020.
- ^ "Group Health Research Institute awarded $15 million in ARRA grants". eurekalert.org. October 5, 2009. Retrieved October 20, 2020.
- ^ "Stopping hormones might help breast cancer to regress". eurekalert.org. February 28, 2012. Retrieved October 20, 2020.
- ^ "Computer-aided detection does not improve breast cancer screening". kpwashingtonresearch.org. September 28, 2015. Retrieved October 20, 2020.
- ^ "Mailed self-sampling kits helped more women get screened for cervical cancer". washington.edu. November 6, 2019. Retrieved October 20, 2020.
External links
edit- Diana Buist publications indexed by Google Scholar